# Selank

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/selank (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: A Russian-developed anxiolytic peptide with nootropic properties that reduces anxiety without sedation or dependence.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/selank

\*\*Selank (TP-7)\*\* — A Russian-developed anxiolytic peptide with nootropic properties that reduces anxiety without sedation or dependence. \*\*Category:\*\* Cognitive & Neuro · \*\*Status:\*\* Research Only ### Description Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as an analog of tuftsin (a natural immunomodulatory tetrapeptide). It has been approved in Russia and Ukraine for the treatment of generalized anxiety disorder and as a nootropic agent. Selank is notable for producing robust anxiolytic effects comparable to benzodiazepines in animal models, but without the sedation, cognitive impairment, tolerance development, or withdrawal syndrome associated with benzodiazepine use. This makes it particularly attractive for long-term anxiety management and cognitive enhancement. It has also demonstrated immunomodulatory properties, increasing the activity of natural killer (NK) cells and T-lymphocytes, and has been studied for antiviral effects. ### Key Characteristics - \*\*Molecular Formula:\*\* C33H57N11O9 - \*\*Molecular Weight:\*\* 751.87 Da - \*\*Half-Life:\*\* ~1–2 minutes (intranasal) - \*\*Administration Routes:\*\* Intranasal (preferred), Subcutaneous injection - \*\*Typical Dose:\*\* 250–500 mcg - \*\*Frequency:\*\* 2–3x daily ### Investigated Benefits - Reduced anxiety without sedation - Improved cognitive function - Enhanced memory and learning - No tolerance or dependence - Immunomodulatory effects \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action Selank’s anxiolytic mechanism involves multiple neurotransmitter systems. It modulates the GABAergic system by increasing the expression of GABA-A receptor subunits, enhancing inhibitory neurotransmission without directly binding to benzodiazepine sites (which explains the absence of tolerance and dependence). It also influences serotonin metabolism by inhibiting enkephalin-degrading enzymes, increasing the availability of endogenous opioid peptides that modulate anxiety. Selank increases BDNF (brain-derived neurotrophic factor) expression in the hippocampus and prefrontal cortex, supporting neuroplasticity and cognitive function. Its tuftsin-like structure confers immunomodulatory effects: it activates T-lymphocytes and NK cells through tuftsin receptors on immune cells, and has demonstrated antiviral properties in influenza models. Intranasal administration provides rapid CNS delivery through olfactory nerve pathways. ### Dosing & Protocol - \*\*Typical Dose:\*\* 250–500 mcg - \*\*Frequency:\*\* 2–3x daily - \*\*Cycle Length:\*\* 2–4 weeks - \*\*Administration:\*\* Intranasal (preferred) \*\*Protocol Notes:\*\* Intranasal administration provides rapid CNS delivery. Effects felt within 15–30 minutes. Can be used acutely for anxiety or in cycles for nootropic benefits. ### Reconstitution Guide Available as nasal spray. Injectable: add 1 mL bacteriostatic water to 1 mg vial. ### Storage Information Refrigerate. Nasal spray: use within 30 days of opening. ### Quality & Sourcing Standards When sourcing Selank for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Approved in Russia for anxiety disorders 2. Demonstrated anxiolytic effects comparable to diazepam in animal models 3. Increased BDNF expression in multiple studies ### Evidence Level \*\*Moderate Evidence\*\* — Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited. ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.